ITRI-90

ITRI-90 (0.01-20 μM; 24 h) degrades full-length AR and truncated AR variant (AR-V) proteins in LNCaP, CWR22Rv1 and VCaP cells, with DC₅₀ values ranging from 2.12 to 8.67 μM for full-length AR degradation and from 0.29 to 4.72 μM for AR-V7 degradation^[1].
ITRI-90 (10 μM; eluted after 24 h of treatment and observed at different time points) induces sustained degradation of AR protein in LNCaP, CWR22Rv1 and VCaP cells, and this effect persists for an extended period after drug withdrawal^[1].
ITRI-90 (0.5-5 μM; 16-24 h) inhibits DHT-induced KLK3 promoter activity and downregulates the mRNA expression of AR and AR-V7 target genes in LNCaP and CWR22Rv1 cells^[1].

ITRI-90 (5-10 μM; 24 h-8 days) reverses the Enzalutamide-induced upregulation of AR and AR-V expression and significantly inhibits the proliferation of drug-resistant cells in Enzalutamide (HY-70002)-acquired resistant C4-2B/EnzR cells and VCaP cells treated with short-term Enzalutamide^[1].
ITRI-90 (0.01-100 μM; 24 h-7 days) inhibits cell viability, activates Caspase 3/7, and induces apoptosis in LNCaP, CWR22Rv1, and VCaP cells, while it does not cause AR degradation or exhibit significant cytotoxicity in normal prostate epithelial PNT2 cells and AR-negative PC3 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.